The Mitsubishi Tanabe Pharma Group engages Healthcare Professionals (HCPs) and Healthcare Organisations (HCOs) across Europe.

We are committed to ensuring transparency in our interaction with HCPs and HCOs. In accordance with the EFPIA Code of Transfers of Value from Pharmaceutical Companies 2014, details of Transfers of Value made to HCPs and HCOs in Europe by the Mitsubishi Tanabe Pharma Group can be found below. 

The Methodology applied in preparing and collating these figures is available here in English*, French* and German*.

If you are a Healthcare Professional and have any questions regarding the figures disclosed, please contact: 
Finance@mt-pharma-eu.com.

2020 Transfers of Value

Austria
Research & Development EUR 27,567.52
Non-Research & Development EUR 39,013.10
Belgium
Research & Development EUR 41,677.50
Non-Research & Development EUR 7,500.00
Bulgaria
Research & Development EUR 0.00
Non-Research & Development EUR 0.00
Croatia
Research & Development EUR 0.00
Non-Research & Development EUR 0.00
Cyprus
Research & Development EUR 0.00
Non-Research & Development EUR 0.00
Czech Republic
Research & Development EUR 4,536.23
Non-Research & Development EUR 0.00
Denmark
Research & Development EUR 0.00
Non-Research & Development EUR 0.00
Estonia
Research & Development EUR 0.00
Non-Research & Development EUR 0.00
Finland
Research & Development EUR 0.00
Non-Research & Development EUR 0.00
France
Research & Development EUR 441,861.75
Non-Research & Development EUR 5,000.00
Germany
Research & Development EUR 39,402.76
Non-Research & Development EUR 81,295.45
Greece
Research & Development EUR 0.00
Non-Research & Development EUR 0.00
Hungary
Research & Development HUF 430,000.00
Non-Research & Development HUF 0.00
Ireland
Research & Development EUR 193,699.64
Non-Research & Development EUR 0.00
Italy
Research & Development EUR 89,773.40
Non-Research & Development EUR 0.00
Latvia
Research & Development EUR 0.00
Non-Research & Development EUR 0.00
Lithuania
Research & Development EUR 0.00
Non-Research & Development EUR 0.00
Malta
Research & Development EUR 0.00
Non-Research & Development EUR 0.00
The Netherlands
Research & Development EUR 173,296.00
Non-Research & Development EUR 0.00
Norway
Research & Development EUR 0.00
Non-Research & Development EUR 0.00
Poland
Research & Development EUR 50,792.89
Non-Research & Development EUR 0.00
Portugal
Research & Development EUR 0.00
Non-Research & Development EUR 0.00
Romania
Research & Development EUR 0.00
Non-Research & Development EUR 0.00
Russia
Research & Development EUR 5,716.46
Non-Research & Development EUR 0.00
Serbia
Research & Development RSD 1,643,600.00
Non-Research & Development RSD 0.00
Slovakia
Research & Development EUR 3,877.50
Non-Research & Development EUR 0.00
Slovenia
Research & Development EUR 0.00
Non-Research & Development EUR 0.00
Spain
Research & Development EUR 17,238.30
Non-Research & Development EUR 0.00
Sweden
Research & Development SEK 180,900.00
Non-Research & Development SEK 0.00
Switzerland
Research & Development CHF 56,243.20
Non-Research & Development CHF 50,592.82
Turkey
Research & Development EUR 0.00
Non-Research & Development EUR 0.00
Ukraine
Research & Development UAH 17,250.00
Non-Research & Development UAH 0.00
United Kingdom
Research & Development GBP 24,302.95
Non-Research & Development GBP 36,266.67

 

* The Mitsubishi Tanabe Pharma Group has established legal entities in the United Kingdom, Germany and Switzerland and therefore disclosure is made according to local requirements for these countries